Evolving drug regulatory landscape in China: A clinical pharmacology perspective

In order to encourage innovative medicine to address Chinese unmet medical needs, China has changed its drug regulatory landscape to speed up access to new medicines. In order to understand the fast‐changing landscape and to enable planning of more global drug development programs and study designs...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Weifeng, Huang, Ying, Zhou, Diansong, Huang, Yao, Chen, Yingxue, Ren, Song, Li, Yan, Wu, Shengqian, Zhao, Xiaoying, Song, Xuyang, Wang, Haidong, Jin, Yuwen, Yu, Hongtao, Zhang, Li, Li, Yunfei, Boulton, David, Shen, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301550/
https://www.ncbi.nlm.nih.gov/pubmed/33503308
http://dx.doi.org/10.1111/cts.12987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301550/
https://www.ncbi.nlm.nih.gov/pubmed/33503308
http://dx.doi.org/10.1111/cts.12987

Ejemplares similares